Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | CD274 dec exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| CD274 dec exp | lung non-small cell carcinoma | predicted - sensitive | Avelumab + Pepinemab | Phase Ib/II | Actionable | In a Phase Ib/II trial, the combination treatment of Bavencio (avelumab) and Pepinemab (VX15/2503) resulted in a partial response or stable disease in 97% (28/29) of non-small cell lung cancer patients with decreased CD274 (PD-L1) expression, and the combination therapy was found to have greater clinical activity compared to other studies with single agent Bavencio (avelumab) treatment in a similar patient population (PMID: 33820783; NCT03268057). | 33820783 |